In a first, HKEX receives IPO pitch from local biotech looking to make it big in crowded antibodies field
A Hong Kong-based antibody maker has filed for an IPO on the HKEX, marking the first truly homegrown company to take advantage of new rules that allow pre-revenue biotechs to list on the stock exchange.
Founder and CEO Shawn Leung calls SinoMab an industry pioneer in the region, having started out in 2002 with support from Morningside — at a time the city’s leaders appeared more interested in “rationalization” of Chinese medicine. Leung, an Oxford-educated local who trained in the US first as a postdoc then at Immunomedics, came up with his own framework for humanizing antibodies. That formed the basis of SinoMab’s current pipeline, which comprises a lead anti-CD22 drug, a BTK inhibitor, and four other preclinical mAbs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.